RVPH — REVIVA PHARMACEUTICALS HOLDINGS, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1742927 ·
Last close
$0.50
Market Cap
$6.56M
52W High
$16.00
52W Low
$0.26
ADV30
24,330
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,617,543 | -2,447,831 | 21,140,590 | 19,889,960 | 5,933,345 |
| Mar 2026 | 0 | — | -3,271,952 | -3,195,987 | 23,559,636 | 22,190,231 | 6,119,155 |
| Dec 2025 | 0 | — | -3,559,041 | -3,367,679 | 15,923,198 | 14,438,792 | 7,275,553 |
| Sep 2025 | 0 | — | -4,029,841 | -4,010,773 | 14,332,649 | 13,183,259 | 9,782,914 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,201,741
Investing CF
—
Financing CF
$37,102,568
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.67
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-187,333,939
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-16,602,592
Pretax Income TTM
$-16,611,027
Interest Exp TTM
$8,435
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,200,031 | -19,864,902 | 15,923,198 | 7,275,553 | 8,647,645 | -24,594,643 |
| Dec 2024 | 0 | -30,798,889 | -29,918,802 | 15,503,088 | 14,690,516 | 812,572 | -33,543,916 |
| Dec 2023 | 0 | -39,503,636 | -39,260,837 | 23,700,388 | 17,981,672 | 5,718,716 | -28,324,353 |
| Dec 2022 | 0 | -28,228,758 | -28,261,442 | 18,923,675 | 10,529,429 | 8,394,246 | -18,960,581 |
TTM Snapshot
Revenues TTM
$314,613
NetIncome TTM
$-16,628,049
OpCashFlow TTM
—
Assets (Latest)
$23,559,636
Forward EPS
$-0.85
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.50 · call volume: 52 · put volume: 0
Expected Move to 2026-10-16:
±$0.38
(76.00%) —
implied range
$0.12 –
$0.88
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XCUR | EXICURE, INC. | $6.55M | $1.00 | — |
| ALZN | Alzamend Neuro, Inc. | $6.47M | $1.34 | — |
| MDCX | Medicus Pharma Ltd. | $6.44M | $0.10 | — |
| LEXX | Lexaria Bioscience Corp. | $6.74M | $3.20 | — |
| NRSN | NeuroSense Therapeutics Ltd. | $6.79M | $3.58 | — |
News headlines (Yahoo Finance, 1h cache)
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
2026-06-23 12:00 · Yahoo
RVPH: First Quarter 2026 Results
2026-05-27 10:55 · Yahoo
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 20:35 · Yahoo
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
2026-04-23 12:00 · Yahoo
RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2
2026-04-01 12:35 · Yahoo
Reviva Announces Letter to Shareholders
2026-04-15 12:00 · Yahoo
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
2026-03-30 10:05 · Yahoo
Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans
2026-04-21 02:46 · Yahoo
RVPH: Shareholder Letter Introduces New IP
2026-04-20 09:30 · Yahoo
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-12 20:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.